We host world-leading programmes in basic, translational and clinical neuroscience research. Our integrated approach allows for the swift transfer of basic biomedical findings to the clinical setting. We deliver evidence-based therapies of high impact for the benefit of society and the economy.
The UK Risk-Sharing Scheme for interferon-beta and glatiramer acetate in multiple sclerosis. Outcome of the year-6 analysis.
Duddy M. and Palace J., (2016), Pract Neurol, 16, 4 - 6
Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group.
McGuigan C. et al, (2016), J Neurol Neurosurg Psychiatry, 87, 117 - 125
Intrusive memories to traumatic footage: the neural basis of their encoding and involuntary recall.
Clark IA. et al, (2016), Psychol Med, 46, 505 - 518
Investigating the dependence of the calibration parameter M on echo time.
Hare HV. and Bulte DP., (2016), Magn Reson Med, 75, 556 - 561
The quality of our research was ranked first in the UK in Unit of Assessment 4 of the Research Excellence Framework 2014. Ninety-five per cent of our submission was rated as world leading or internationally excellent, and we scored 100% for the quality of our research and training environment.
MRC BRAIN NETWORK DYNAMICS UNIT
The MRC BNDU focuses on the moment-to-moment interactions between nerve cells that are critical for brain functions. It operates over two sites at the Nuffield Department of Clinical Neurosciences and the Department of Pharmacology.
Watch some of our researchers presenting their work.
Listen to departmental seminars and special lectures.